{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:29:31Z","timestamp":1785774571624,"version":"3.56.0"},"reference-count":38,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>Pharmacy-driven antibiotic dosing services have been shown to improve clinical outcomes in adult patients. This study evaluated the effect of a pharmacist-driven antimicrobial dosing service on the percentage of therapeutic serum concentrations achieved following initial vancomycin or aminoglycoside dosing regimens. A secondary objective was to determine the effect of the dosing service on nephrotoxicity in pediatric patients.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This single-center, retrospective study used data obtained from an electronic medical record to evaluate the utility of a pharmacist-driven vancomycin or aminoglycoside dosing protocol. Assessments of target, subtherapeutic, and supratherapeutic serum concentrations were evaluated. The occurrence of changes in serum creatinine and presentation of acute kidney injury (AKI) were also determined.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>The incidence (n [%]) of a therapeutic initial serum concentration was not statistically significant between pre-protocol and post-protocol groups (21 [46.7%] vs 22 [48.9%], respectively; p = 0.834). The incidence of initial supratherapeutic concentrations (19 [42.2%] vs 7 [15.6%]; p = 0.005) and the average number of supratherapeutic concentrations per antibiotic course (0.76 vs 0.26; p = 0.01) were higher in the pre-protocol group compared with the post-protocol group. The incidence of AKI was significantly lower in the post-protocol group (2.2% vs 13.3%; p = 0.049).<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Implementation of a pharmacist-driven dosing service did not affect the likelihood of achieving an initial therapeutic concentration. However, it did reduce the likelihood of both supratherapeutic concentrations and AKI. Additional studies in pediatric patients are needed to affirm the use of pharmacist dosing services.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-27.4.340","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T19:17:09Z","timestamp":1652123829000},"page":"340-346","source":"Crossref","is-referenced-by-count":5,"title":["Implementation of a Pharmacist-Driven Vancomycin and Aminoglycoside Dosing Service in a Pediatric Hospital"],"prefix":"10.5863","volume":"27","author":[{"given":"Sara W.","family":"Hovey","sequence":"first","affiliation":[{"name":"Rush University Medical Center (SWH, JLJ, KMW, BNV), Rush Children's Hospital, Chicago, IL; Chicago State University (BNV), College of Pharmacy, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Rush University Medical Center (SWH, JLJ, KMW, BNV), Rush Children's Hospital, Chicago, IL; Chicago State University (BNV), College of Pharmacy, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Welsh","sequence":"additional","affiliation":[{"name":"Rush University Medical Center (SWH, JLJ, KMW, BNV), Rush Children's Hospital, Chicago, IL; Chicago State University (BNV), College of Pharmacy, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty N.","family":"Vu","sequence":"additional","affiliation":[{"name":"Rush University Medical Center (SWH, JLJ, KMW, BNV), Rush Children's Hospital, Chicago, IL; Chicago State University (BNV), College of Pharmacy, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"9","key":"i2331-348X-27-4-340-b1","series-title":"Ann Pharmacother","first-page":"1009","article-title":"Evaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center","volume":"49","year":"2015","unstructured":"Marquis\n              KA,\n            \n            \n              DeGrado\n              JR,\n            \n            \n              Labonville\n              S,\n            \n          \n          .\n\t\t\t\t\tEvaluation of a pharmacist-directed vancomycin dosing and monitoring pilot program at a tertiary academic medical center.\n\t\t\t\t\tAnn Pharmacother.\n\t\t\t\t\t2015;\n\t\t\t\t\t49(\n\t\t\t\t\t9):\n\t\t\t\t\t1009\u2013\n\t\t\t\t\t1014."},{"issue":"4","key":"i2331-348X-27-4-340-b2","series-title":"Int J Clin Pharmacol Ther","first-page":"284","article-title":"Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin","volume":"53","year":"2015","unstructured":"Masuda\n              N,\n            \n            \n              Maiguma\n              T,\n            \n            \n              Komoto\n              A,\n            \n          \n          .\n\t\t\t\t\tImpact of pharmacist intervention on preventing nephrotoxicity from vancomycin.\n\t\t\t\t\tInt J Clin Pharmacol Ther.\n\t\t\t\t\t2015;\n\t\t\t\t\t53(\n\t\t\t\t\t4):\n\t\t\t\t\t284\u2013\n\t\t\t\t\t291."},{"issue":"9","key":"i2331-348X-27-4-340-b3","series-title":"Consult Pharm","first-page":"505","article-title":"Impact of a pharmacist-initiated vancomycin monitoring program","volume":"31","year":"2016","unstructured":"Smith\n              AP,\n            \n            \n              Millares-Sipin\n              CA,\n            \n            \n              James\n              M,\n            \n            \n              Cohen\n              H.\n            \n          \n          Impact of a pharmacist-initiated vancomycin monitoring program.\n\t\t\t\t\tConsult Pharm.\n\t\t\t\t\t2016;\n\t\t\t\t\t31(\n\t\t\t\t\t9):\n\t\t\t\t\t505\u2013\n\t\t\t\t\t510."},{"issue":"1","key":"i2331-348X-27-4-340-b4","series-title":"Chemotherapy","first-page":"3","article-title":"Safety and outcome of pharmacy-led vancomycin dosing and monitoring","volume":"61","year":"2016","unstructured":"Momattin\n              H,\n            \n            \n              Zogheib\n              M,\n            \n            \n              Homoud\n              A,\n            \n            \n              Al-Tawfiq\n              JA.\n            \n          \n          Safety and outcome of pharmacy-led vancomycin dosing and monitoring.\n\t\t\t\t\tChemotherapy.\n\t\t\t\t\t2016;\n\t\t\t\t\t61(\n\t\t\t\t\t1):\n\t\t\t\t\t3\u2013\n\t\t\t\t\t7."},{"issue":"10","key":"i2331-348X-27-4-340-b5","series-title":"Clin Infect Dis","first-page":"51","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","year":"2016","unstructured":"Barlam\n              TF,\n            \n            \n              Cosgrove\n              SE,\n            \n            \n              Abbo\n              LM,\n            \n          \n          .\n\t\t\t\t\tImplementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2016;\n\t\t\t\t\t62(\n\t\t\t\t\t10):\n\t\t\t\t\t51."},{"issue":"6","key":"i2331-348X-27-4-340-b6","series-title":"J Pediatr Pharmacol Ther","first-page":"494","article-title":"Survey evaluating the practice of children's hospitals having pharmacist collaborative drug therapy management protocols","volume":"21","year":"2016","unstructured":"Welsh\n              C,\n            \n            \n              Miah\n              R,\n            \n            \n              Girotto\n              J.\n            \n          \n          Survey evaluating the practice of children's hospitals having pharmacist collaborative drug therapy management protocols.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2016;\n\t\t\t\t\t21(\n\t\t\t\t\t6):\n\t\t\t\t\t494\u2013\n\t\t\t\t\t501."},{"issue":"3","key":"i2331-348X-27-4-340-b7","series-title":"J Pediatr Pharmacol Ther","first-page":"177","article-title":"ASHP-PPAG guidelines for providing pediatric pharmacy services in hospitals and health systems","volume":"23","year":"2018","unstructured":"Eiland\n              LS,\n            \n            \n              Benner\n              K,\n            \n            \n              Gumpper\n              KF,\n            \n          \n          .\n\t\t\t\t\tASHP-PPAG guidelines for providing pediatric pharmacy services in hospitals and health systems.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2018;\n\t\t\t\t\t23(\n\t\t\t\t\t3):\n\t\t\t\t\t177\u2013\n\t\t\t\t\t191."},{"key":"i2331-348X-27-4-340-b8","article-title":"Vancomycin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs","unstructured":"Vancomycin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs.\n\t\t\t\t\tHudson, OH:\n\t\t\t\t\tLexi-Comp, Inc.\n\t\t\t\t\tUpdated July, 2013. Accessed January 1, 2017. http:\/\/online.lexi.com"},{"key":"i2331-348X-27-4-340-b9","article-title":"Gentamicin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs","unstructured":"Gentamicin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs.\n\t\t\t\t\tHudson, OH:\n\t\t\t\t\tLexi-Comp, Inc.\n\t\t\t\t\tUpdated July, 2013.Accessed January 1, 2017. http:\/\/online.lexi.com"},{"key":"i2331-348X-27-4-340-b10","article-title":"Tobramycin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs","unstructured":"Tobramycin. Lexi-Comp Online, Pediatric & Neonatal Lexi-Drugs.\n\t\t\t\t\tHudson, OH:\n\t\t\t\t\tLexi-Comp, Inc.\n\t\t\t\t\tUpdated July, 2013.Accessed January 1, 2017. http:\/\/online.lexi.com"},{"key":"i2331-348X-27-4-340-b11","series-title":"Drug Prescribing in Renal Failure","year":"1999","unstructured":"Aronoff\n              GR,\n            \n            \n              Berns\n              JS,\n            \n            \n              Brier\n              ME,\n            \n          \n          .\n\t\t\t\t\tDrug Prescribing in Renal Failure.\n\t\t\t\t\t4th ed.\n\t\t\t\t\tPhiladelphia, PA:\n\t\t\t\t\tAmerican College of Physicians;\n\t\t\t\t\t1999."},{"key":"i2331-348X-27-4-340-b12","series-title":"Clin Infect Dis","first-page":"1","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"51","year":"2011","unstructured":"Liu\n              C,\n            \n            \n              Bayer\n              A,\n            \n            \n              Cosgrove\n              SE,\n            \n          \n          .\n\t\t\t\t\tClinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2011;\n\t\t\t\t\t51:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t38."},{"key":"i2331-348X-27-4-340-b13","series-title":"Am J Health-Syst Pharm","first-page":"82","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","year":"2009","unstructured":"Rybak\n              M,\n            \n            \n              Lomaestro\n              B,\n            \n            \n              Rotschafer\n              JC,\n            \n          \n          .\n\t\t\t\t\tTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.\n\t\t\t\t\tAm J Health-Syst Pharm.\n\t\t\t\t\t2009;\n\t\t\t\t\t66:\n\t\t\t\t\t82\u2013\n\t\t\t\t\t98."},{"key":"i2331-348X-27-4-340-b14","series-title":"Perit Dial Int","first-page":"S29","article-title":"Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis","volume":"32","year":"2012","unstructured":"Warady\n              BA,\n            \n            \n              Schaefer\n              F,\n            \n            \n              Holloway\n              M,\n            \n          \n          .\n\t\t\t\t\tConsensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis.\n\t\t\t\t\tPerit Dial Int.\n\t\t\t\t\t2012;\n\t\t\t\t\t32:\n\t\t\t\t\tS29\u2013\n\t\t\t\t\tS86."},{"issue":"5","key":"i2331-348X-27-4-340-b15","series-title":"Pediatr Infect Dis J","first-page":"462","article-title":"Use of vancomycin in pediatrics","volume":"29","year":"2010","unstructured":"Dehority\n              W.\n            \n          \n          Use of vancomycin in pediatrics.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2010;\n\t\t\t\t\t29(\n\t\t\t\t\t5):\n\t\t\t\t\t462\u2013\n\t\t\t\t\t464."},{"issue":"3","key":"i2331-348X-27-4-340-b16","series-title":"Pharmacotherapy","first-page":"361","article-title":"Pediatric obesity: pharmacokinetic alterations and effects on antimicrobial dosing","volume":"37","year":"2017","unstructured":"Natale\n              S,\n            \n            \n              Bradley\n              J,\n            \n            \n              Nguyen\n              WH,\n            \n          \n          .\n\t\t\t\t\tPediatric obesity: pharmacokinetic alterations and effects on antimicrobial dosing.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2017;\n\t\t\t\t\t37(\n\t\t\t\t\t3):\n\t\t\t\t\t361\u2013\n\t\t\t\t\t378."},{"issue":"3","key":"i2331-348X-27-4-340-b17","series-title":"J Pediatr","first-page":"422","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","year":"2011","unstructured":"McKamy\n              S,\n            \n            \n              Hernandez\n              E,\n            \n            \n              Jahng\n              M,\n            \n          \n          .\n\t\t\t\t\tIncidence and risk factors influencing the development of vancomycin nephrotoxicity in children.\n\t\t\t\t\tJ Pediatr.\n\t\t\t\t\t2011;\n\t\t\t\t\t158(\n\t\t\t\t\t3):\n\t\t\t\t\t422\u2013\n\t\t\t\t\t426."},{"issue":"6","key":"i2331-348X-27-4-340-b18","series-title":"Pharmacotherapy","first-page":"598","article-title":"Acute kidney injury during vancomycin therapy in critically ill children","volume":"33","year":"2013","unstructured":"Totapally\n              BR,\n            \n            \n              Machado\n              J,\n            \n            \n              Lee\n              H,\n            \n          \n          .\n\t\t\t\t\tAcute kidney injury during vancomycin therapy in critically ill children.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2013;\n\t\t\t\t\t33(\n\t\t\t\t\t6):\n\t\t\t\t\t598\u2013\n\t\t\t\t\t602."},{"issue":"2","key":"i2331-348X-27-4-340-b19","series-title":"Pediatrics","first-page":"463","article-title":"Neonatal acute kidney injury","volume":"136","year":"2015","unstructured":"Selewski\n              DT,\n            \n            \n              Charlton\n              JR,\n            \n            \n              Jetton\n              JG,\n            \n          \n          .\n\t\t\t\t\tNeonatal acute kidney injury.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2015;\n\t\t\t\t\t136(\n\t\t\t\t\t2):\n\t\t\t\t\t463\u2013\n\t\t\t\t\t473."},{"issue":"9","key":"i2331-348X-27-4-340-b20","series-title":"J Pharm Pharmacol","first-page":"1091","article-title":"The kinetic profile of gentamicin in premature neonates","volume":"52","year":"2000","unstructured":"Rocha\n              MJ,\n            \n            \n              Almeida\n              AM,\n            \n            \n              Afonso\n              E,\n            \n          \n          .\n\t\t\t\t\tThe kinetic profile of gentamicin in premature neonates.\n\t\t\t\t\tJ Pharm Pharmacol.\n\t\t\t\t\t2000;\n\t\t\t\t\t52(\n\t\t\t\t\t9):\n\t\t\t\t\t1091\u2013\n\t\t\t\t\t1097."},{"issue":"7","key":"i2331-348X-27-4-340-b21","series-title":"Pediatr Infect Dis J","first-page":"742","article-title":"Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients","volume":"34","year":"2015","unstructured":"Ringenberg\n              T,\n            \n            \n              Robinson\n              C,\n            \n            \n              Meyers\n              R,\n            \n          \n          .\n\t\t\t\t\tAchievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2015;\n\t\t\t\t\t34(\n\t\t\t\t\t7):\n\t\t\t\t\t742\u2013\n\t\t\t\t\t747."},{"issue":"11","key":"i2331-348X-27-4-340-b22","series-title":"Br J Clin Pharmacol","first-page":"2591","article-title":"Vancomycin is commonly under-dosed in critically ill children and neonates","volume":"85","year":"2019","unstructured":"Sosnin\n              N,\n            \n            \n              Curtis\n              N,\n            \n            \n              Cranswick\n              N,\n            \n          \n          .\n\t\t\t\t\tVancomycin is commonly under-dosed in critically ill children and neonates.\n\t\t\t\t\tBr J Clin Pharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t85(\n\t\t\t\t\t11):\n\t\t\t\t\t2591\u2013\n\t\t\t\t\t2598."},{"key":"i2331-348X-27-4-340-b23","series-title":"Curr Ther Res Clin Exp","first-page":"51","article-title":"Prospective validation of neonatal vancomycin dosing regimens is urgently needed","volume":"76","year":"2014","unstructured":"Vandendriessche\n              A,\n            \n            \n              Allegaert\n              K,\n            \n            \n              Cossey\n              V,\n            \n          \n          .\n\t\t\t\t\tProspective validation of neonatal vancomycin dosing regimens is urgently needed.\n\t\t\t\t\tCurr Ther Res Clin Exp.\n\t\t\t\t\t2014;\n\t\t\t\t\t76:\n\t\t\t\t\t51\u2013\n\t\t\t\t\t57."},{"key":"i2331-348X-27-4-340-b24","series-title":"Int J Pediatr","first-page":"470364","article-title":"An evaluation of initial vancomycin dosing in infants, children, and adolescents","volume":"2011","year":"2011","unstructured":"Broome\n              L,\n            \n            \n              So\n              TY.\n            \n          \n          An evaluation of initial vancomycin dosing in infants, children, and adolescents.\n\t\t\t\t\tInt J Pediatr.\n\t\t\t\t\t2011;\n\t\t\t\t\t2011:\n\t\t\t\t\t470364."},{"issue":"9","key":"i2331-348X-27-4-340-b25","series-title":"Pharmaco-therapy","first-page":"871","article-title":"Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations","volume":"31","year":"2011","unstructured":"Frymoyer\n              A,\n            \n            \n              Guglielmo\n              BJ,\n            \n            \n              Wilson\n              SD,\n            \n          \n          .\n\t\t\t\t\tImpact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.\n\t\t\t\t\tPharmaco-therapy.\n\t\t\t\t\t2011;\n\t\t\t\t\t31(\n\t\t\t\t\t9):\n\t\t\t\t\t871\u2013\n\t\t\t\t\t876."},{"issue":"7","key":"i2331-348X-27-4-340-b26","series-title":"J Antimicrob Chemother","first-page":"2074","article-title":"Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates","volume":"70","year":"2015","unstructured":"Valitalo\n              PA,\n            \n            \n              van den Anker\n              JN,\n            \n            \n              Allegaert\n              K,\n            \n          \n          .\n\t\t\t\t\tNovel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates.\n\t\t\t\t\tJ Antimicrob Chemother.\n\t\t\t\t\t2015;\n\t\t\t\t\t70(\n\t\t\t\t\t7):\n\t\t\t\t\t2074\u2013\n\t\t\t\t\t2077."},{"issue":"1","key":"i2331-348X-27-4-340-b27","series-title":"Antimicrob Agents Chemother","first-page":"e01304","article-title":"Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by Gram-negative bacteria","volume":"61","year":"2016","unstructured":"Bijleveld\n              YA,\n            \n            \n              van den Heuvel\n              ME,\n            \n            \n              Hodiamont\n              CJ,\n            \n          \n          .\n\t\t\t\t\tPopulation pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by Gram-negative bacteria.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2016;\n\t\t\t\t\t61(\n\t\t\t\t\t1):\n\t\t\t\t\te01304\u2013\n\t\t\t\t\te01316."},{"issue":"1","key":"i2331-348X-27-4-340-b28","series-title":"J Crit Care","first-page":"1","article-title":"Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function","volume":"15","year":"2000","unstructured":"Glover\n              ML,\n            \n            \n              Cole\n              E,\n            \n            \n              Wolfsdorf\n              J.\n            \n          \n          Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.\n\t\t\t\t\tJ Crit Care.\n\t\t\t\t\t2000;\n\t\t\t\t\t15(\n\t\t\t\t\t1):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t4."},{"issue":"9","key":"i2331-348X-27-4-340-b29","series-title":"PLoS One","first-page":"e0203453","article-title":"Effects of pharmacist intervention in vancomycin treatment for patients with bacteremia due to methicillin-resistant Staphylococcus aureus","volume":"13","year":"2018","unstructured":"Komoto\n              A,\n            \n            \n              Maiguma\n              T,\n            \n            \n              Teshima\n              D,\n            \n          \n          .\n\t\t\t\t\tEffects of pharmacist intervention in vancomycin treatment for patients with bacteremia due to methicillin-resistant Staphylococcus aureus.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2018;\n\t\t\t\t\t13(\n\t\t\t\t\t9):\n\t\t\t\t\te0203453."},{"issue":"1","key":"i2331-348X-27-4-340-b30","series-title":"J Chemother","first-page":"42","article-title":"Pharmacist-driven aminoglycoside quality improvement program","volume":"21","year":"2009","unstructured":"Greenwood\n              BC,\n            \n            \n              Szumita\n              PM,\n            \n            \n              Lowry\n              CM.\n            \n          \n          Pharmacist-driven aminoglycoside quality improvement program.\n\t\t\t\t\tJ Chemother.\n\t\t\t\t\t2009;\n\t\t\t\t\t21(\n\t\t\t\t\t1):\n\t\t\t\t\t42\u2013\n\t\t\t\t\t45."},{"issue":"3","key":"i2331-348X-27-4-340-b31","series-title":"J Oncol Pharm Pract","first-page":"448","article-title":"Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients","volume":"22","year":"2016","unstructured":"Abdel Hadi\n              O,\n            \n            \n              Al Omar\n              S,\n            \n            \n              Nazer\n              LH,\n            \n          \n          .\n\t\t\t\t\tVancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.\n\t\t\t\t\tJ Oncol Pharm Pract.\n\t\t\t\t\t2016;\n\t\t\t\t\t22(\n\t\t\t\t\t3):\n\t\t\t\t\t448\u2013\n\t\t\t\t\t453."},{"issue":"6","key":"i2331-348X-27-4-340-b32","series-title":"Pediatr Cardiol","first-page":"761","article-title":"Gentamicin dosing for pediatric patients with congenital heart disease","volume":"31","year":"2010","unstructured":"Moffett\n              BS,\n            \n            \n              Bork\n              SJ,\n            \n            \n              Mott\n              AR.\n            \n          \n          Gentamicin dosing for pediatric patients with congenital heart disease.\n\t\t\t\t\tPediatr Cardiol.\n\t\t\t\t\t2010;\n\t\t\t\t\t31(\n\t\t\t\t\t6):\n\t\t\t\t\t761\u2013\n\t\t\t\t\t765."},{"issue":"12","key":"i2331-348X-27-4-340-b33","series-title":"Pharmacotherapy","first-page":"1288","article-title":"Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis","volume":"33","year":"2013","unstructured":"Stockmann\n              C,\n            \n            \n              Sherwin\n              CM,\n            \n            \n              Zobell\n              JT,\n            \n          \n          .\n\t\t\t\t\tPopulation pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2013;\n\t\t\t\t\t33(\n\t\t\t\t\t12):\n\t\t\t\t\t1288\u2013\n\t\t\t\t\t1296."},{"issue":"4","key":"i2331-348X-27-4-340-b34","series-title":"J Pediatr Pharmacol Ther","first-page":"305","article-title":"Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support","volume":"23","year":"2018","unstructured":"Zylbersztajn\n              BL,\n            \n            \n              Izquierdo\n              G,\n            \n            \n              Santana\n              RC,\n            \n          \n          .\n\t\t\t\t\tTherapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2018;\n\t\t\t\t\t23(\n\t\t\t\t\t4):\n\t\t\t\t\t305\u2013\n\t\t\t\t\t310."},{"issue":"4","key":"i2331-348X-27-4-340-b35","series-title":"J Clin Pharm Ther","first-page":"484","article-title":"Effect of hypothermia treatment on gentamicin pharmacokinetics in neonates with hypoxic-ischaemic encephalopathy: a systematic review and meta-analysis","volume":"43","year":"2018","unstructured":"Choi\n              DW,\n            \n            \n              Park\n              JH,\n            \n            \n              Lee\n              SY,\n            \n            \n              An\n              SH.\n            \n          \n          Effect of hypothermia treatment on gentamicin pharmacokinetics in neonates with hypoxic-ischaemic encephalopathy: a systematic review and meta-analysis.\n\t\t\t\t\tJ Clin Pharm Ther.\n\t\t\t\t\t2018;\n\t\t\t\t\t43(\n\t\t\t\t\t4):\n\t\t\t\t\t484\u2013\n\t\t\t\t\t492."},{"issue":"4","key":"i2331-348X-27-4-340-b36","series-title":"Pediatr Infect Dis J","first-page":"347","article-title":"Altered gentamicin serum concentrations in obese pediatric patients","volume":"30","year":"2011","unstructured":"Choi\n              JJ,\n            \n            \n              Moffett\n              BS,\n            \n            \n              McDade\n              EJ,\n            \n            \n              Palazzi\n              DL.\n            \n          \n          Altered gentamicin serum concentrations in obese pediatric patients.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2011;\n\t\t\t\t\t30(\n\t\t\t\t\t4):\n\t\t\t\t\t347\u2013\n\t\t\t\t\t349."},{"issue":"11","key":"i2331-348X-27-4-340-b37","series-title":"Antimicrob Agents Chemother","first-page":"6454","article-title":"Association between vancomycin trough concentration and area under the concentration-time curve in neonates","volume":"58","year":"2014","unstructured":"Frymoyer\n              A,\n            \n            \n              Hersh\n              AL,\n            \n            \n              El-Komy\n              MH,\n            \n          \n          .\n\t\t\t\t\tAssociation between vancomycin trough concentration and area under the concentration-time curve in neonates.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2014;\n\t\t\t\t\t58(\n\t\t\t\t\t11):\n\t\t\t\t\t6454\u2013\n\t\t\t\t\t6461."},{"issue":"11","key":"i2331-348X-27-4-340-b38","series-title":"Am J Health Syst Pharm","first-page":"835","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","year":"2020","unstructured":"Rybak\n              MJ,\n            \n            \n              Le\n              J,\n            \n            \n              Lodise\n              TP,\n            \n          \n          .\n\t\t\t\t\tTherapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.\n\t\t\t\t\tAm J Health Syst Pharm.\n\t\t\t\t\t2020;\n\t\t\t\t\t77(\n\t\t\t\t\t11):\n\t\t\t\t\t835\u2013\n\t\t\t\t\t864."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/4\/article-p340.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/4\/340\/3060035\/i2331-348x-27-4-340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/4\/article-p340.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/4\/article-p340.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:34:28Z","timestamp":1747355668000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/4\/article-p340.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.4.340","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}